The Commission has signed a joint procurement framework contract with
the pharmaceutical company Gilead for the supply of up to 500,000
treatment courses of Veklury, the brand name for Remdesivir, and the
opportunity to increase supply beyond the 500,000 treatment courses.
There are 36 signatories of the Joint Procurement Agreement
participating in this joint procurement, including all EU countries,
the EEA countries of Norway and Iceland*, the UK, as well as six
candidate countries and potential candidates (Albania, the Republic of
North Macedonia, Montenegro, Serbia, Kosovo** and Bosnia and
Herzegovina). All participating countries can now place their orders to
procure Veklury directly. Veklury is at this stage the only medicine
with a conditional marketing authorisation in the EU for the treatment
of COVID-19 patients needing oxygen supply.
Read more at: Coronavirus: Remdesivir
